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Abstract
Background: Sepsis is one of the serious disorders in clinical practice. Recent studies found toll-like receptors 4
(TLR4) played an important role in sepsis. In this study, we tried to find the influence of Corilagin on TLR4 signal
pathways in vitro and in vivo.
Methods: The cellular and animal models of sepsis were established by LPS and then interfered with Corilagin.
Real-time PCR and western blot were employed to detect the mRNA and protein expressions of TLR4, MyD88, TRIF
and TRAF6. ELISA was used to determine the IL-6 and IL-1β levels in supernatant and serum.
Results: The survival rate was improved in the LPS + Corilagin group, and the mRNA and protein expressions of
TLR4, MyD88, TRIF and TRAF6 were significantly decreased than that in the LPS group both in cellular and animal
models (P < 0.01). The pro-inflammatory cytokines IL-6 and IL-1β were greatly decreased in the LPS + Corilagin
group both in supernatant and serum (P < 0.01).
Conclusions: Corilagin exerts the anti-inflammatory effects by down-regulating the TLR4 signaling molecules to
ameliorate the extreme inflammatory status in sepsis.
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Background
Sepsis is one of the serious complications of trauma,
shock, burns and other critical patients, and can induce
multiple organ dysfunction syndromes (MODS) [1]. The
core mechanism of sepsis is inflammation. During the
process of serious infection, pro-inflammatory cytokines
pour out, leading to systemic inflammation reaction syn-
dromes (SIRS) [2]. Sepsis and SIRS are the different
phases of same pathological process.
Recently, studies found toll-like receptors (TLRs)
played an important role in sepsis, especially in early
stage as producing of pro-inflammatory cytokines [3].
Recognition of pathogens and persistent systemic in-
flammation cascade are linked by TLRs. Thereby,
regulation of TLRs may ameliorates conditions of pro-
gression and prognosis of sepsis [4, 5]. TLR4 is the first
toll-like associated protein found in the human and is
distributed in B/T lymphocytes, macrophages, liver,
spleen and lung [6]. Gram-negative bacterial LPS is
the mainly ligand. As gram-negative bacteria are the
main pathogens in sepsis, in critical patients TLR4 as
the main protein in natural immunity plays a vital
role in activating monocyte-macrophage system, trig-
gering inflammatory cascade, intensifying inflamma-
tion, and resulting in sepsis eventually [7, 8].
TLR4 signals were transduced through MyD88 and
TRIF pathways. The classic MyD88 pathway plays a key
role in production of pro-inflammatory cytokines. TLR4
receives stimulation such as LPS, sharing downstream
molecule TIRAP with TLR2. Then MyD88 is activated
and TRAF6 receives the signal and promotes the pro-
duction of pro-inflammatory cytokines. Additionally,
MAPK and NEMO take part in the generation as well
[9]. Meanwhile, in TRIF pathway TLR4 sharing
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downstream molecule TRAM with TLR3, and then
TRAF6 receives signals to produce pro-inflammatory cy-
tokines. Simultaneously, activated TRAF3 promotes the
type I interferon via IRF3. Thereby, focusing on TLR4
and key molecules in the signaling pathways may help to
find a new way to understand controlling extreme in-
flammatory status in sepsis.
Corilagin (C27H22O18) is identified in several plants
[10]. Our previous studies has found that Corilagin was
effective in anti-inflammation, hepatic protection, anti-
oxidant and anti-viral encephalitis [11–13]. Corilagin
could also ameliorate schistosomiasis-associated liver
fibrosis by in S. japonicum-infected Balb/c mice and
IL-13-induced macrophages and hepatic satellite cells
[14–17]. Based on anti-inflammatory and antibacterial
activity of Corilagin and our experience on inflammation
[18], we would explore the effect of Corilagin to treat
sepsis by interfering with TLR4 signaling pathway.
In this study, we set up the cellular model with
RAW264.7 cells stimulated by LPS and established
sepsis animal model and then administered the models
with Corilagin, hoping to find the exact mechanisms of




Trizol reagent, RNAios and Real-time PCR kit were ob-
tained from TaKaRa Company (Dalian, China). Anti-
MyD88, anti-TRAF6, anti-TRIF and anti-TLR4 antibodies
were offered from Abcam Biotechnology (MA, USA). LPS
was taken from Sigma-Aldrich (MO, USA). The immuno-
histochemistry kits and HRP-labeled secondary antibodies
were bought from Boster Biotechnology (Wuhan, China).
The IL-1β and IL-6 ELISA kit were purchased from Dke-
wei Biotechnology (Beijing, China). Corilagin was received
from China National institutes for food and drug control.
Cell administration
RAW264.7 cells were bought from Xiangya Central
Laboratory. The cells were cultured in DMEM medium
containing 10% fetal bovine serum (FBS) in the incuba-
tor at 37 °C, 5% CO2 and saturated humidity. As the
cells grew up to 80%, serum-free DMEM medium was
added for incubation overnight. RAW264.7 cells were di-
vided into three groups, the Corilagin group, model
group and normal group. The Corilagin group was stim-
ulated by LPS (1 mg/ml) for 2 h and then Corilagin
(0.25 mg/ml) was added. The model group incubated
with LPS (1 mg/ml) only. The normal group without any
treatment was as negative control. 24 h later the cells
were harvested for total RNA isolation and proteins
extraction. The cultural supernatants were collected for
ELISA. The procedures were repeated for three times.
Animals and treatment
Thirty male Balb/c mice, weighting 19 ~ 25 g, 6 ~ 8 weeks
old, were purchased from Hubei Provincial Center for
Disease and Prevention. The mice were feed in 22 ~ 25 °C
temperature and 50-60% humidity for one week. Then the
animals were randomly divided into 3 groups, the LPS +
Corilagin group, LPS group and control group, with 10
mice in each group. The LPS + Corilagin group and LPS
group were given LPS 20 mg/kg intraperitoneally. The
LPS + Corilagin group was given Corilagin (40 mg/kg)
orally after LPS administration, and the LPS group was
administrated with equivalent volume of saline. The con-
trol group was given normal saline intraperitoneally and
orally instead of LPS and Corilagin. 12 h later, all the mice
were sacrificed after anesthetized by the 10% chloral
hydrate. The liver tissues were stored in a refrigerator of
minus −80 °C for total RNA extraction and western-blot
testing. All animal study protocols were approved by the
Ethics Committee of Huazhong University of Science and
Technology [19].
Histological examination
The liver, colon, lung, brain and kidney tissues were
fixed in 4% formalin and embedded in paraffin. Four mi-
crometers serial sections were obtained for haematoxylin
and eosin (HE) staining to observe the liver pathological
changes. The procedure was referenced by our past
experiment [20, 21].
Total RNA isolation and quantitative real-time PCR
The procedure abided by our past experiment [22]. Total
RNA was isolated from the liver tissues by using RNAiso
Plus (Takara, Dalian, China), and reverse transcription
was performed following the protocol of kit (TaKaRa
Primescript RT Master Mix Perfect Real Time. Code:
DRR036S). Then the samples were incubated at 37 °C
for 15 min and at 85 °C for 5 s. After the template
cDNA was synthesized the amplification steps were
followed with the instruction of kit (TaKaRa SYBR Premix
Ex Taq, Code: DRR041S) and the reaction conditions
were 95 °C 30 s; 95 °C 5 s, 60 °C 30 s, 40 cycles;
95 °C 15 s, 60 °C 1 min, 95 °C 15 s. The results were
analyzed by using 2-△△CT method. GAPDH was used
as the internal control. The procedure were repeated
for three times. All the primers for quantitative real-





MyD88-forward, 5’- GCCAGAGTGGAAAGCAGTGT -3’
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MyD88- reverse, 5’- CGTTGGGGCAGTAGCAGATA -3’
TRIF-forward, 5’- GCAGAGTCGGGGTAACAAGA -3’
TRIF-reverse, 5’- CCAGAAGGTGGTGCTCAAATA -3’
TRAF6-forward, 5’- GCCGAAATGGAAGCACAG -3’
TRAF6-reverse, 5’- CAGGGCTATGGATGACAACA -3’
Western blot analysis
The procedure was followed by our past experiment
[23, 24]. The expression of TLR-4 and associated
signaling molecule proteins were detected by western-
blot assay. The cells of liver tissue proteins (50 μg)
from each sample were separated on SDS-PAGE, and
then transferred to nitrocellulose filter membranes
which were blocked overnight with 5% nonfat milk in
TBST. Blots were probed over night at 4 °C with
rabbit polyclonal TLR4 (diluted as 1:500), MyD88 (diluted
as 1:500), TRIF (diluted as 1:500) and TRAF6 (diluted as
1:500) and then were followed by incubated with HRP-
labeled secondary antibody for two hours before being
washed 5–6 times in TBST. After further washing with
TBST, ECL was added to identify the immunoreactive
bands. The densitometry analysis of the immunoreactive
bands was performed using the Fuji ultrasonic-doppler
Fig. 1 The mRNA and protein expression of TLR4, MyD88, TRAF6 and
TRIF in cellular models. a Effect of Corilagin on mRNA expression of
TLR4 and MyD88 in cellular model. b Effect of Corilagin on mRNA
expression of TRAF6 and TRIF in cellular model.※p < 0.01 compared
with the control group. #p < 0.01 compared with the LPS group.
c Effect of corilagin on TLR4, MyD88, TRIF and TRAF6 protein
expression in cellular model. Western blot assay showed the TLR4,
MyD88, TRIF and TRAF6 proteins expression were greatly increased in
LPS group, while in the Corilagin + LPS groups, the proteins were
decreased compared with that in the LPS group
Fig. 2 Effect of Corilagin on expression of IL-1β, IL-6 in cell supernatants.
Effect of Corilagin on expression of IL-1β, IL-6 in cell supernatants.
※p < 0.01 compared with the control group. #p < 0.01 compared
with the LPS group
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velocity profile (UVP) system and Image J program. The
procedure was repeated for three times.
Detection of IL-1β and IL-6 expression by ELISA
The procedure abided by our past experiment [25]. The
expressions of IL-1β and IL-6 in cell supernatants and
mice serum were tested by ELISA. Prepare all reagents
before starting assay procedure. All standards and samples
were added in 5 duplicates. For setting standard wells, the
standard was diluted to 1000 pg/ml, 500 pg/ml, 250 pg/ml,
125 pg/ml, 62.5 pg/ml, 31.25 pg/ml, 15.625 pg/ml, 0 pg/ml
in standard wells. Then the 100ul samples were added to
testing well and 50ul of biotinylated antibody (1:100) were
added to each well. By covering with an adhesive strip and
the plate was incubated for 90 min at 37 °C. Then each
well was washed for 4 times, and each well was added with
100ul diluted streptavidin-HRP (1:100) and incubated for
30 min at 37 °C. After repeating the washing process,
100ul TMB was added to each well and the plate was incu-
bated for 10 min at 37 °C before the stop solution was
added. The standard curve was generated by plotting the
average 50 nm OD.
Statistical analysis
The statistics were expressed as the means ± SE. Com-
parisons between groups were performed with one-way
ANOVA test and Student’s t-test. All data were analyzed
by using SPSS12.0 statistic software. P < 0.05 was regard
as statistically significant difference [26].
Results
Effect of Corilagin on mRNA expression of TLR4,
MyD88, TRIF and TRAF6 in cellular model
In the LPS group the mRNA levels of TLR4, MyD88,
TRIF and TRAF6 were significantly increased when com-
pared with the control group (p < 0.01). With Corilagin
intervention, the gene expression of TLR4, MyD88, TRIF
and TRAF6 were significantly reduced when compared
with Corilagin + LPS group (p < 0.01) (Fig. 1a and b).
Effect of Corilagin on protein expression of TLR4, MyD88,
TRIF and TRAF6 in cellular model
Western-blotting assay was employed to test the changes
of TLR4, MyD88, TRIF and TRAF6 proteins (Fig. 1c).
The proteins were greatly increased in LPS group when
compared with the control group, while in Corilagin +
LPS groups the proteins were decreased when compared
with the LPS group.
Effect of Corilagin on expression of IL-1β, IL-6 in cell
supernatants
The expression of IL-1β and IL-6 in cell supernatants
was tested by ELISA. In the LPS group the IL-1β, IL-6
levels were significantly increased when compared with
the control group (p < 0.01). With Corilagin interven-
tion, IL-1β, IL-6 expression were significantly reduced
when compared with the LPS group (p < 0.01) (Fig. 2).
Effect of Corilagin on survival rate in animal model
Mice survival rate in LPS + Corilagin group was much
higher than that in LPS group. (Fig. 3).
Effect of Corilagin on mRNA expression of TLR4,
MyD88, TRIF and TRAF6 in animal model
In the LPS group the mRNA levels of TLR4, MyD88,
TRIF and TRAF6 were significantly increased when com-
pared with the control group (p < 0.01). With Corilagin
intervention, the gene expression of TLR4, MyD88, TRIF
and TRAF6 were significantly reduced when compared
with the LPS group (p < 0.01) (Fig. 4a and b).
Effect of Corilagin on protein expression of TLR4, MyD88,
TRIF and TRAF6 in animal model
Western-blot assay was employed to test the changes of
TLR4, MyD88, TRIF and TRAF6 proteins in the liver
(Fig. 4C). The proteins were greatly increased in LPS
group when compared with the control group, while in
LPS + Corilagin groups the proteins were decreased
when compared with the LPS group.
Fig. 3 The overall survival of the mice. Within 12 h, mice survival in Corilagin + LPS group was much higher than in LPS group
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Effect of Corilagin on expression of IL-1β, IL-6 in mice
serum
The expression of IL-1β and IL-6 in mouse serum was
tested by ELISA. In the LPS group the IL-1β, IL-6 levels
were significantly increased when compared with the
control group (p < 0.01). With Corilagin intervention,
IL-1β, IL-6 expression were significantly reduced when
compared with the LPS group (p < 0.01) (Fig. 5).
Effect of Corilagin on liver histopathology
Pathological changes have been observed in the liver,
colon, lung, brain and kidney tissues. In the liver, patho-
logical changes were not typical. In lung and brain, inter-
stitial cells showed obvious edema. There were no obvious
changes in colon and kidney (Fig. 6).
Discussion
As important pattern recognition receptors (PPRs), TLRs
play a pivotal role in innate immunity. TLRs identify a var-
iety of pathogen-associated molecular patterns (PAMPs)
or danger-associated molecular patterns (DAMPs), includ-
ing teichoic acid, LPS, peptidoglycan etc. [27]. TLRs
express on sorts of immune cells such as macrophages,
master cells, monocytes, neutrophils, eosinophils, and so
Fig. 4 The mRNA and protein expression TLR4, TRAF6, MyD88 and
TRIF in animal models. a Effect of Corilagin on mRNA expression of
TLR4 and TRAF6 in animal model. b Effect of Corilagin on mRNA
expression of MyD88 and TRIF in animal model.※p < 0.01
compared with the control group. #p < 0.01 compared with the LPS
group. c Effect of corilagin on TLR4, MyD88, TRIF and TRAF6 protein
expression in animal model. Western blot assay showed the TLR4,
MyD88, TRIF and TRAF6 proteins expression were greatly increased
in LPS group, with Corilagin intervention, the proteins were
decreased compared with that in the LPS group
Fig. 5 Effect of Corilagin on expression of IL-1β, IL-6 in mouse
serum. Effect of Corilagin on expression of IL-1β, IL-6 in mouse
serum.※p < 0.01 compared with the control group. #p < 0.01
compared with the LPS group
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on. As an important molecule of acquired immune, TLR4
activates mononuclear phagocyte system, leading to a cas-
cade of inflammation through MyD88 and TRIF pathways
resulting in SIRS and sepsis eventually [28]. Therefore,
regulating the TLR4 signaling pathways has become an
important therapeutic target in sepsis [5].
Currently, medications for TLR4 were explored in labs
and preclinical researches. TLR4 antagonist Eritoran
Fig. 6 Pathological changes have been observed. a LPS + Corilagin group; b LPS group; c Control group. In the liver, pathological changes were
not obvious. In lung and brain, interstitial cells showed obvious edema. There was no obvious changes in colon and kidney
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have been used in experimental study and the efficacy
and safety of Eritoran for clinical use are under further
evaluation [29]. An anti-TLR4/MD2 monoclonal anti-
body could decrease lethality in the process of sepsis
caused by implantation of a stent in mice [30]. Studies
also have shown that blocking TLR2 or TLR4 resulted in
decreasing disease severity in sepsis [31]. In our study,
we evaluated the therapeutic potential of Corilagin in
sepsis with hope to find a new way to control the ex-
treme inflammatory status of sepsis.
MyD88 and TRIF pathways are the downstream mole-
cules of TLR4. MyD88 pathway is the classical pathway,
inducing production of pro-inflammatory cytokines.
TRIF pathway produces pro-inflammatory cytokines and
type I interferon simultaneously [32]. In our study, we
looked forward to finding whether Corilagin contains
the anti-inflammatory ability and which way it works.
Therefore we selected key signaling molecules TLR-4,
MyD88, TRAF6 and TRIF to evaluate the effect of
Corilagin in TLR4 signaling pathway.
TLR4 signal can be beneficial in pathogen removing at
early stage, but subsequent cascade release of pro-
inflammatory cytokines may cause lethal effects [33]. In
our study, with Corilagin intervention the expression of
TLR4 were greatly decreased in the inflammatory phase,
resulting in lowered expression of downstream mole-
cules MyD88, TRAF6, TRIF and inflammatory cytokines
IL-1β and IL-6.
TLR4 sharing with TRL2 downstream molecules TIRAP,
and then the signal activated MyD88. As the important
downstream molecular of MyD88, TRAF6 expression was
reduced in the study. Furthermore, TLR4 sharing TRIF
signaling pathway with TLR3, which can also activates
TRAF6 in producing pro-inflammatory cytokines. Corila-
gin showed the capability in down-regulating TRAF6 and
TRIF signaling pathway in extreme inflammation status,
which demonstrated that Corialgin might have the poten-
tial to control outbreak of inflammatory cascade in sepsis.
IL-1β is mainly generated by monocytes. It promotes
the production of NO, and then aggregates the inflamma-
tory chemokines and adhesion molecules to expand the
inflammatory response. IL-6 also is a monocyte-derived
cytokine, as an important acute phase reaction medium in
promoting inflammation [34]. In our study, Corilagin re-
duced the production both in vitro and in vivo, indicating
Corilagin possessed the anti-inflammatory capability.
Conclusion
In our study, Corilagin showed capability of inhibiting the
expression of TLR4 signaling molecules in both MyD88
and TRIF signaling pathways, which demonstrated that
Corilagin might be a potential agent to rescue the patients
from extreme inflammatory status in sepsis.
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